Sanofi Healthcare India Pvt. Ltd. has announced the marketing authorization of Dupixent® (dupilumab), a pioneering biologic treatment for adults suffering from moderate-to-severe atopic dermatitis. This approval marks a significant step forward in managing a disease characterized by intense itching, dry skin, redness, and other discomforting symptoms, especially for patients whose condition hasn’t responded to topical prescription therapies or where these treatments are not recommended.
Unlike traditional treatments that broadly suppress the immune system, Dupixent® directly targets the type 2 inflammation that underlies atopic dermatitis. Already approved in the U.S., the European Union, Japan, and more than 60 other countries, it is the first and only biologic medicine in India that has proven to significantly improve disease symptoms and quality of life measures for this challenging skin condition.
Dupixent®, which is the result of a global collaboration between Sanofi and Regeneron, has already been administered to over 600,000 patients globally and is now poised to change the treatment landscape for adults suffering from moderate to severe atopic dermatitis in India.
